Romanian state-owned pharmaceutical manufacturer Antibiotice posted 32.6 million lei in net profit, in the first quarter of this year, down 13% compared to the same period last year, according to a company report sent to the Bucharest Stock Exchange on last Wednesday."The responsible and rigorous conduct of activities in the first 3 months of 2025, while constantly monitoring the impact The Future Together business plan had on our objective meeting led to a gross profit return of 21.9%, 3% higher than that achieved in the same period of the previous year. In the same period, total revenues and total expenses are proportional with the same evolution index, determining a higher gross profit return cumulated with the clawback tax of 27.8% compared to 26.9% in the same period of the previous year, which leads to greater balance and efficiency in the first quarter of 2025," the report states.The company recorded a gross profit of 35.343 million lei in the first quarter, down 10% compared to that reported at the end of the first quarter of 2024.The net turnover (revenue from customer contracts) achieved in the period January-March 2025 is worth 161.12 million lei, of which 86.12 million lei was achieved on the Romanian market and 75 million lei on the international market.Antibiotice SA is listed on the Bucharest Stock Exchange under the symbol ATB, in the Premium category, since April 16, 1997.